Articles from Allosteric Bioscience, Inc.

Allosteric Bioscience, Inc. is utilizing Genetics, Genomics, Systems Biology, Quantum Computing, Advanced Proprietary AI and Proprietary Molecular Technologies for understanding and controlling the Molecular Mechanism of Aging and Longevity with the goal of optimizing the aging process and extending longevity.

Allosteric Bioscience, Inc. is delineating the Molecular Mechanism of Aging and Longevity with the goal of optimizing the aging process and extending longevity. It is utilizing Genomics, Biology, Genetics, Quantum Computing, Advanced Proprietary AI and Proprietary Molecular Technologies.

Allosteric Bioscience, Inc. (ABI), has announced today that it has licensed technology from Johns Hopkins University for the treatment or prevention of sarcopenia which is a serious medical condition involving the loss of muscle mass, quality, and strength and is a significant part of the natural aging process. Sarcopenia can result in reduced quality of life due to falls, bone fractures, and disability.

Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity. The chemical leads were designed by ABI employing Quantum Computing and Advanced Artificial Intelligence (AI) as part of the company’s platform.

Allosteric Bioscience, Inc., announced today that Dr. Susan Michaelis has joined its Scientific Advisory Board (SAB). Dr. Michaelis is a leading scientist working on fundamental cell and molecular processes related to human health, disease and longevity and she is a Professor of Cell Biology in the Johns Hopkins University School of Medicine.